Change language dansk English suomi svenska

Generate Estimates Confirm Cancel Hide empty rows Show hidden rows DummyText

PHARMAVEST ApS Estimate generation in progress, please wait... 0%

Quicksearch from your own companies XBRLDenmark Analyst: XBRLDenmark

Loading... Loading... Loading... Loading...   Loading...

1000.0 Bankruptcy Risk  2018 2018/12 2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024e N/A 2025e N/A Bankruptcy risk for industry   1.5% 1.5% 1.5% 1.5% 1.5% 1.5% 1.1% 1.1%   Bankruptcy risk   2.1% 1.4% 1.9% 1.2% 1.0% 0.9% 8.6% 8.6%   Credit score (0-100)   69 79 70 82 86 89 29 29   Credit rating   A A A A A A BB BB   Credit limit (kDKK)   0.2 37.9 1.4 190.4 344.5 569.6 0.0 0.0   How are these values calculated?   View the automatically generated explanation of bankruptcy risk 1000.0 Income statement (kDKK)  2018 2018/12 2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024e N/A 2025e N/A Net sales   0 0 0 0 0 0 0 0   Gross profit   1,085 1,771 1,159 1,762 1,771 1,975 0.0 0.0   EBITDA   552 1,254 547 1,070 1,080 1,156 0.0 0.0   EBIT   473 1,142 464 992 1,034 1,114 0.0 0.0   Pre-tax profit (PTP)   472.6 1,071.5 383.8 837.6 879.8 1,287.3 0.0 0.0   Net earnings   360.2 817.8 281.3 618.0 680.5 1,013.4 0.0 0.0   Pre-tax profit without non-rec. items   473 1,072 384 838 880 1,287 0.0 0.0     See the entire income statement 1000.0 Balance sheet (kDKK)  2018 2018/12 2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024e N/A 2025e N/A Tangible assets total   344 231 149 161 19.8 615 0.0 0.0   Shareholders equity total   2,945 3,643 3,804 4,302 4,857 5,746 4,746 4,746   Interest-bearing liabilities   8.6 32.9 5.2 12.6 16.3 30.1 0.0 0.0   Balance sheet total (assets)   3,733 4,319 5,192 5,293 6,042 6,838 4,746 4,746   Net Debt   -1,106 -1,882 -1,912 -2,951 -3,946 -3,438 -4,746 -4,746     See the entire balance sheet 1000.0 Volume  2018 2018/12 2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024e N/A 2025e N/A Net sales   0 0 0 0 0 0 0 0   Net sales growth   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Gross profit   1,085 1,771 1,159 1,762 1,771 1,975 0.0 0.0   Gross profit growth   220.9% 63.2% -34.6% 52.0% 0.5% 11.6% -100.0% 0.0%   Employees   1 1 1 1 1 1 0 0   Employee growth %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% -100.0% 0.0%   Employee expenses   0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0   Balance sheet total (assets)   3,733 4,319 5,192 5,293 6,042 6,838 4,746 4,746   Balance sheet change%   15.8% 15.7% 20.2% 1.9% 14.2% 13.2% -30.6% 0.0%   Added value   552.4 1,254.0 546.9 1,069.9 1,112.7 1,156.3 0.0 0.0   Added value %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Investments   -26 -225 -165 -66 -186 553 -615 0   Net sales trend   0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0   EBIT trend   1.0 2.0 3.0 4.0 5.0 5.0 0.0 0.0   1000.0 Profitability  2018 2018/12 2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024e N/A 2025e N/A EBITDA %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   EBIT %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   EBIT to gross profit (%)   43.6% 64.4% 40.1% 56.3% 58.4% 56.4% 0.0% 0.0%   Net Earnings %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Profit before depreciation and extraordinary items %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Pre tax profit less extraordinaries %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   ROA %   13.6% 26.7% 8.6% 16.4% 18.5% 17.3% 0.0% 0.0%   ROI %   17.1% 32.4% 10.9% 21.2% 22.8% 24.1% 0.0% 0.0%   ROE %   13.0% 24.8% 7.6% 15.2% 14.9% 19.1% 0.0% 0.0%   1000.0 Solidity  2018 2018/12 2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024e N/A 2025e N/A Equity ratio %   78.9% 84.3% 73.3% 81.3% 80.4% 84.0% 100.0% 100.0%   Relative indebtedness %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Relative net indebtedness %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Net int. bear. debt to EBITDA, %   -200.1% -150.1% -349.6% -275.8% -365.4% -297.3% 0.0% 0.0%   Gearing %   0.3% 0.9% 0.1% 0.3% 0.3% 0.5% 0.0% 0.0%   Net interest   0 0 0 0 0 0 0 0   Financing costs %   20.6% 10.7% 130.6% 277.2% 1,178.8% 27.1% 0.0% 0.0%   1000.0 Liquidity  2018 2018/12 2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024e N/A 2025e N/A Quick Ratio   2.5 3.9 2.3 4.0 4.2 4.5 0.0 0.0   Current Ratio   4.1 5.9 3.6 5.2 5.2 5.9 0.0 0.0   Cash and cash equivalent   1,114.2 1,915.2 1,917.1 2,963.3 3,961.8 3,468.1 0.0 0.0   1000.0 Capital use efficiency  2018 2018/12 2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024e N/A 2025e N/A Trade debtors turnover (days)   0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0   Trade creditors turnover (days)   0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0   Current assets / Net sales %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   Net working capital   2,421.6 3,292.2 3,600.7 3,527.6 3,487.3 3,044.1 0.0 0.0   Net working capital %   0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%   1000.0 Employee efficiency  2018 2018/12 2019 2019/12 2020 2020/12 2021 2021/12 2022 2022/12 2023 2023/12 2024e N/A 2025e N/A Net sales / employee   0 0 0 0 0 0 0 0   Added value / employee   552 1,254 547 1,070 1,113 1,156 0 0   Employee expenses / employee   0 0 0 0 0 0 0 0   EBITDA / employee   552 1,254 547 1,070 1,080 1,156 0 0   EBIT / employee   473 1,142 464 992 1,034 1,114 0 0   Net earnings / employee   360 818 281 618 680 1,013 0 0